Janssen wins FDA nod for Symtuza but the once-daily HIV drug must now find its place in the market

19th July 2018 Uncategorised 0

Johnson & Johnson has won FDA approval for a new once-a-day HIV drug, adding to its growing portfolio of treatment options for the condition. Now J&J must find a way to distinguish the drug in an increasingly crowded market that includes hot-selling Biktarvy, Gilead Sciences’ single-dose combo.

More: Janssen wins FDA nod for Symtuza but the once-daily HIV drug must now find its place in the market
Source: fierce